Palisade Bio logo

Palisade Bio

PALI | NASDAQ
Chart Builder DCF Calculator
$1.03
-$0.09 (-8.04%)
At close: Nov 16, 2026, 4:00 PM ET
$1.03
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-8.04%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
50.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #268/1021 (Top 26%)

Key Statistics

Market Data

Market Cap $218.39M
1D Range
1.02 1.11
52W Range
1.01 2.80

Valuation (TTM)

PE -4.68
PB 1.94
EV/EBITDA -2.33

Valuation (NTM)

Forward PE N/A
Forward PEG 0.09
Price Target $4.50
Loading financial charts...

Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the ...

Sector Healthcare
Industry Biotechnology
Employees 14
IPO Date Mar 30, 2007
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Next Earnings
Mar 31, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$4.50
Upside
+336.89%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.